Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M1i
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
M1i is a potent small-molecule inhibitor targeting methyltransferase-like protein 1 (METTL1), an enzyme responsible for depositing tRNA 7-Methylguanosine (m7G) modification. It is being investigated as a potential therapeutic agent for acute myeloid leukemia (AML). M1i inhibits METTL1's m7G methyltransferase activity, leading to a reduction in tRNA m7G levels and disruption of the tRNA^phe_GAA/HCK/CXCR4 signaling cascade, which is crucial for leukemia stem cell (LSC) self-renewal and bone marrow homing. Preclinical studies have shown that M1i significantly reduces LSC frequency, delays leukemogenesis, and prolongs survival in various myeloid leukemia models.
02
Targets
METTL1
Beyond the preview
Go deeper on M1i.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on M1i.